Elizabeth A Mittendorf

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Implementation of the american college of surgeons oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy?
    Elizabeth A Mittendorf
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 21:2468-73. 2014
  2. doi request reprint Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy
    Elizabeth A Mittendorf
    Department of Surgical Oncology, Unit 1484, The University of TexasMDAnderson Cancer Center, 1400 Pressler St, Houston, TX 77030, USA
    Ann Surg 257:173-9. 2013
  3. doi request reprint Melanoma adrenal metastasis: natural history and surgical management
    Elizabeth A Mittendorf
    Department of Surgical Oncology, Unit 444, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Surg 195:363-8; discussion 368-9. 2008
  4. doi request reprint What is an hour-lecture worth?
    Donald N Reed
    Department of Surgery, Michigan State University College of Human Medicine, SPB 655, 1200 E Michigan Ave, Lansing, MI 48912, USA
    Am J Surg 195:379-81; discussion 381. 2008
  5. doi request reprint Mechanisms of T-cell inhibition: implications for cancer immunotherapy
    Elizabeth A Mittendorf
    Department of Surgical Oncology, Unit 444, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Expert Rev Vaccines 9:89-105. 2010
  6. ncbi request reprint CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37)
    Elizabeth A Mittendorf
    University of Texas MD Anderson Cancer Center, Department of Surgical Oncology, Houston, TX 77030, USA
    Expert Opin Biol Ther 9:71-8. 2009
  7. ncbi request reprint Significance and management of micrometastases in patients with breast cancer
    Elizabeth A Mittendorf
    The University of Texas MD Anderson Cancer Center, Department of Surgical Oncology, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 7:1451-61. 2007
  8. doi request reprint Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer
    Amanda L Kong
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:6287-96. 2012
  9. doi request reprint Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    Asna Amin
    Department of Surgery, General Surgery Service, Walter Reed Army Medical Center, Washington, DC, USA
    Cancer Immunol Immunother 57:1817-25. 2008
  10. pmc Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer
    Abigail S Caudle
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 28:1821-8. 2010

Detail Information

Publications83

  1. ncbi request reprint Implementation of the american college of surgeons oncology group z1071 trial data in clinical practice: is there a way forward for sentinel lymph node dissection in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy?
    Elizabeth A Mittendorf
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 21:2468-73. 2014
    ..We are currently evaluating the efficacy of TAD in axillary staging after neoadjuvant chemotherapy. ..
  2. doi request reprint Impact of chemotherapy sequencing on local-regional failure risk in breast cancer patients undergoing breast-conserving therapy
    Elizabeth A Mittendorf
    Department of Surgical Oncology, Unit 1484, The University of TexasMDAnderson Cancer Center, 1400 Pressler St, Houston, TX 77030, USA
    Ann Surg 257:173-9. 2013
    ..This study was performed to evaluate long-term local-regional control rates after breast-conserving therapy (BCT) for patients undergoing surgery before or after neoadjuvant chemotherapy...
  3. doi request reprint Melanoma adrenal metastasis: natural history and surgical management
    Elizabeth A Mittendorf
    Department of Surgical Oncology, Unit 444, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Am J Surg 195:363-8; discussion 368-9. 2008
    ..Few data exist regarding melanoma metastasis to the adrenal gland. We reviewed our experience to determine the natural history of this condition and the appropriate role for surgical intervention...
  4. doi request reprint What is an hour-lecture worth?
    Donald N Reed
    Department of Surgery, Michigan State University College of Human Medicine, SPB 655, 1200 E Michigan Ave, Lansing, MI 48912, USA
    Am J Surg 195:379-81; discussion 381. 2008
    ..Although there are many ways to convey knowledge, attitudes, and techniques when teaching residents and students, the most optimal method (lecture, online lecture, online tutorial, simulator practice, and so on) is yet to be determined...
  5. doi request reprint Mechanisms of T-cell inhibition: implications for cancer immunotherapy
    Elizabeth A Mittendorf
    Department of Surgical Oncology, Unit 444, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Expert Rev Vaccines 9:89-105. 2010
    ..In this review, we discuss several regulatory mechanisms that act to control effector T-cell responses and identify strategies to circumvent these mechanisms in order to improve clinical responses...
  6. ncbi request reprint CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37)
    Elizabeth A Mittendorf
    University of Texas MD Anderson Cancer Center, Department of Surgical Oncology, Houston, TX 77030, USA
    Expert Opin Biol Ther 9:71-8. 2009
    ..AE37 is an HER2/neu-derived peptide that has been modified to enhance antigen-specific stimulation of Th cells by linkage of the Ii-Key moiety of the MHC class II-associated invariant chain (Ii protein)...
  7. ncbi request reprint Significance and management of micrometastases in patients with breast cancer
    Elizabeth A Mittendorf
    The University of Texas MD Anderson Cancer Center, Department of Surgical Oncology, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 7:1451-61. 2007
    ....
  8. doi request reprint Impact of internal mammary lymph node drainage identified by preoperative lymphoscintigraphy on outcomes in patients with stage I to III breast cancer
    Amanda L Kong
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:6287-96. 2012
    ..Involvement of internal mammary (IM) lymph nodes is associated with a poor prognosis for patients with breast cancer. This study examined the effect of drainage to IM nodes identified by lymphoscintigraphy on oncologic outcomes...
  9. doi request reprint Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    Asna Amin
    Department of Surgery, General Surgery Service, Walter Reed Army Medical Center, Washington, DC, USA
    Cancer Immunol Immunother 57:1817-25. 2008
    ..We have performed clinical trials of E75 + GM-CSF vaccine in disease-free, node-positive and node-negative BCa patients at high recurrence risk and recurrences were noted in both control and vaccine groups...
  10. pmc Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer
    Abigail S Caudle
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 28:1821-8. 2010
    ..Because many of these variables are also associated with response to NCT, novel molecular predictors are needed to identify patients at risk for progression on standard NCT...
  11. ncbi request reprint The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer
    Rosalinda Alvarado
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:3177-84. 2012
    ..Our objective was to evaluate SLN dissection in node-positive patients and to determine whether postchemotherapy ultrasound could select patients for this technique...
  12. ncbi request reprint American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns
    Abigail S Caudle
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:3144-51. 2012
    ..The ACOSOG Z0011 trial has been described as practice-changing. The goal of this study was to determine the impact of the trial on surgeon practice patterns at our institution...
  13. doi request reprint Impact of the american college of surgeons oncology group Z0011 criteria applied to a contemporary patient population
    Min Yi
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 216:105-13. 2013
    ..The aim of this study was to assess applicability of Z0011 results to our patient population and determine what percentage may be affected by these results...
  14. doi request reprint Impact of progression during neoadjuvant chemotherapy on surgical management of breast cancer
    Abigail S Caudle
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 18:932-8. 2011
    ..The goal of this study was to determine the impact of disease progression during NCT on surgical management...
  15. doi request reprint Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients
    Kelly K Hunt
    Department of Surgical Oncology, MD Anderson Cancer Center, The University of Texas, Houston, TX 77030, USA
    Ann Surg 250:558-66. 2009
    ..This study was performed to evaluate the accuracy of SLN surgery for patients undergoing neoadjuvant chemotherapy versus patients undergoing surgery first...
  16. doi request reprint Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine
    Jarrod P Holmes
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, 3851 Roger Brooke Dr, Fort Sam Houston, TX, 78234, USA
    J Clin Oncol 26:3426-33. 2008
    ..We present the results of the first human phase I trial of the Ii-Key hybrid HER-2/neu peptide (AE37) vaccine in disease-free, node-negative breast cancer patients...
  17. pmc Biology, treatment, and outcome in very young and older women with DCIS
    Rosalinda Alvarado
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:3777-84. 2012
    ..This study examines a modern cohort of women with ductal carcinoma-in-situ (DCIS) in order to identify potential differences in clinical presentation, treatments, and outcome based on age...
  18. ncbi request reprint Lymphovascular invasion and lobular histology are associated with increased incidence of isolated tumor cells in sentinel lymph nodes from early-stage breast cancer patients
    Elizabeth A Mittendorf
    Department of Surgical Oncology, Unit 444, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg Oncol 15:3369-77. 2008
    ..Our goal was to identify clinicopathologic features associated with ITC in patients undergoing sentinel lymph node dissection (SLND)...
  19. ncbi request reprint Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer
    Elizabeth A Mittendorf
    Clinical Breast Care Project, Department of Surgery, Walter Reed Army Medical Center, 6900 Georgia Avenue NW, Washington, DC 20307 5001, USA
    Ann Surg Oncol 13:1085-98. 2006
    ..This study was designed to investigate the kinetics of trastuzumab treatment on tumor cells with varying levels of HER2/neu expression and to determine the effect of trastuzumab on HER2/neu-specific cytotoxic T lymphocyte-mediated lysis...
  20. doi request reprint Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer
    Himanshu Nagar
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Radiat Oncol Biol Phys 81:782-7. 2011
    ....
  21. ncbi request reprint Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype
    Rachel L Theriault
    Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Breast Cancer 11:325-31. 2011
    ..This article evaluates the risk of recurrence for patients who have small node-negative breast cancer by age and tumor subtype...
  22. ncbi request reprint Outcomes and predictive factors for salvage therapy after local--regional recurrence following neoadjuvant chemotherapy and breast conserving therapy
    David C Weksberg
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 20:3430-7. 2013
    ..We characterize the clinical course and predictive features of salvage treatment for LRR after breast conserving therapy (BCT) analyzed by initial treatment...
  23. pmc Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy
    Gheath Alatrash
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Immunol 189:5476-84. 2012
    ....
  24. pmc Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    Elizabeth A Mittendorf
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer 118:2594-602. 2012
    ..They previously reported that the vaccine is safe and effective in stimulating expansion of E75-specific cytotoxic T cells. Here, they report 24-month landmark analyses of disease-free survival (DFS)...
  25. doi request reprint The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    Linda C Benavides
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, Houston, Texas 78234, USA
    Clin Cancer Res 15:2895-904. 2009
    ..We have conducted clinical trials with the HER2/neu E75 peptide vaccine in breast cancer patients with varying levels of HER2/neu expression. Vaccine response based on HER2/neu expression level was analyzed...
  26. ncbi request reprint Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer
    Laura S Dominici
    Department of Surgical Oncology, Brigham and Women s Hospital, Boston, MA, USA
    Cancer 116:2884-9. 2010
    ..To the authors' knowledge, the rate of eradication of biopsy-proven axillary lymph node metastases with trastuzumab-containing neoadjuvant chemotherapy regimens has not been previously reported...
  27. doi request reprint Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy
    Ranjna Sharma
    Department of Surgical Oncology, Plastic Surgery, Radiation Oncology, and Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Plast Reconstr Surg 127:1763-72. 2011
    ....
  28. doi request reprint Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database
    Min Yi
    Department of Surgical Oncology, Unit 444, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 17:343-51. 2010
    ..The purpose of this study was to examine differences in survival for patients undergoing SLNB alone versus SLNB with complete ALND...
  29. doi request reprint Results of the first phase 1 clinical trial of the HER-2/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04
    Mark G Carmichael
    Cancer Vaccine Development Program, United States Military Cancer Institute, Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
    Cancer 116:292-301. 2010
    ..GP2, derived from the transmembrane portion of HER-2/neu, has differing binding characteristics and may be more immunogenic than E75. Results of the first phase 1 trial of GP2 peptide vaccine are presented...
  30. ncbi request reprint Staging of breast cancer in the neoadjuvant setting
    Jacqueline S Jeruss
    Department of Surgery, Northwestern University Feinberg School of Medicine and Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois 60611, USA
    Cancer Res 68:6477-81. 2008
    ....
  31. ncbi request reprint Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted?
    Elizabeth FitzSullivan
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 20:4103-12. 2013
    ..We sought to determine the incidence and consequences of close margins in patients with DCIS treated with mastectomy...
  32. ncbi request reprint Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial
    Judy C Boughey
    Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA
    JAMA 310:1455-61. 2013
    ..The application of SLN surgery for staging the axilla following chemotherapy for women who initially had node-positive cN1 breast cancer is unclear because of high false-negative results reported in previous studies...
  33. doi request reprint Optimising radiation treatment decisions for patients who receive neoadjuvant chemotherapy and mastectomy
    Karen E Hoffman
    Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Lancet Oncol 13:e270-6. 2012
    ..Randomised clinical trial data are needed to assess whether postmastectomy radiation therapy can be safely omitted in selected women with good response to neoadjuvant chemotherapy...
  34. pmc Evaluation of a breast cancer nomogram for predicting risk of ipsilateral breast tumor recurrences in patients with ductal carcinoma in situ after local excision
    Min Yi
    Department of Surgical Oncology, Unit 1484, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Houston, TX 77030, USA
    J Clin Oncol 30:600-7. 2012
    ..The aim of our study was to evaluate a published nomogram from Memorial Sloan-Kettering Cancer Center to predict for risk of IBTR in patients with DCIS from our institution...
  35. doi request reprint The GP2 peptide: a HER2/neu-based breast cancer vaccine
    Kevin S Clive
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, Ft Sam Houston, Texas, USA
    J Surg Oncol 105:452-8. 2012
    ....
  36. pmc Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy
    Abigail S Caudle
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Hermann Pressler Drive, Unit 1484, Houston, TX 77030, USA
    Breast Cancer Res 14:R83. 2012
    ....
  37. pmc Implications of constructed biologic subtype and its relationship to locoregional recurrence following mastectomy
    Laura S Dominici
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Breast Cancer Res 14:R82. 2012
    ..We examined the prognostic value of biologic subtype on locoregional recurrence (LRR) after mastectomy in a cohort of low risk women who did not receive adjuvant radiation therapy...
  38. pmc A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia
    Mao Zhang
    Stem Cell Transplantation and Cellular Therapy, Surgical Oncology, and Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Cancer Res 19:247-57. 2013
    ..In this study, we characterize the role of the myeloid azurophil granule protease cathepsin G (CG) as a novel target for AML immunotherapy...
  39. pmc Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors
    Naoki Niikura
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1354, Houston, TX 77030, USA
    J Clin Oncol 30:593-9. 2012
    ..We also compared the overall survival durations of patients with HER2-concordant and -discordant tumors...
  40. pmc Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system
    Min Yi
    The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 29:4654-61. 2011
    ..We hypothesized that differences in biology influence this variation and that addition of biologic markers to AJCC staging improves determination of prognosis...
  41. doi request reprint Occult axillary lymph node metastases do not have prognostic significance in early stage breast cancer
    Yun Wu
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:1507-14. 2012
    ..The clinical significance of occult lymph node metastases has been the subject of debate...
  42. doi request reprint Does blue dye contribute to success of sentinel node mapping for breast cancer?
    Taewoo Kang
    Department of Surgical Oncology, M D Anderson Cancer Center, The University of Texas, Houston, TX, USA
    Ann Surg Oncol 17:280-5. 2010
    ..We sought to evaluate the utilization of blue dye in addition to radioisotope and its relative contribution to sentinel lymph node (SLN) mapping at a high-volume institution...
  43. doi request reprint Ductal carcinoma-in-situ of the breast with subsequent distant metastasis and death
    Robert E Roses
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 18:2873-8. 2011
    ..The rare patient diagnosed with pure ductal carcinoma-in-situ (DCIS) develops distant breast cancer metastases (DM). We sought to identify clinical and pathologic predictors of DM...
  44. pmc Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy
    Elizabeth A Mittendorf
    University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 29:1956-62. 2011
    ..The current study was undertaken to validate this staging system using internal and external cohorts...
  45. ncbi request reprint A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients
    Isabelle Bedrosian
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston Texas, USA
    Cancer 116:2543-8. 2010
    ..This study reported a phase 1 trial conducted in patients with cytologically documented axillary metastasis undergoing axillary lymph node dissection to determine the feasibility and oncologic safety of ARM...
  46. doi request reprint Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines
    Linda C Benavides
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, 3851 Roger Brooke Drive, Ft Sam, Houston, TX 78234, USA
    Expert Rev Vaccines 10:201-10. 2011
    ..077) and GP2 (p = 0.076). All three peptide vaccines were safe and well-tolerated. These findings have led to a clinically relevant optimal vaccine dosing strategy, which may be applicable to other peptide-based cancer vaccines...
  47. doi request reprint Triple-negative breast cancer is not a contraindication for breast conservation
    Farrell C Adkins
    Department of Surgical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 18:3164-73. 2011
    ..Triple-negative breast cancer (TNBC) is an aggressive subtype shown to have a high risk of locoregional recurrence (LRR). The purpose of this study was to determine the impact of operation type on LRR in TNBC patients...
  48. doi request reprint Sentinel lymph node dissection is technically feasible in older breast cancer patients
    Vicente Valero
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Breast Cancer 10:477-82. 2010
    ..This study was undertaken to compare identification rates in patients 70 years of age and older versus those younger than 70 years in a large cohort undergoing sentinel lymph node dissection (SLND)...
  49. pmc Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response
    Elizabeth A Mittendorf
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 72:3153-62. 2012
    ..Taken together, our findings reveal a previously unknown mechanism of antitumor adaptive immunity that links cancer cell uptake of an inflammatory mediator to an effective cytolytic response against an important breast cancer antigen...
  50. doi request reprint Evaluation of the MD Anderson Prognostic Index for local-regional recurrence after breast conserving therapy in patients receiving neoadjuvant chemotherapy
    Catherine L Akay
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:901-7. 2012
    ..The current study was undertaken to evaluate this prognostic index in an independent cohort...
  51. doi request reprint Incorporation of sentinel lymph node metastasis size into a nomogram predicting nonsentinel lymph node involvement in breast cancer patients with a positive sentinel lymph node
    Elizabeth A Mittendorf
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg 255:109-15. 2012
    ..The goal of this study was to construct a nomogram incorporating SLN metastasis size to accurately predict non-SLN involvement in patients with SLN-positive disease...
  52. doi request reprint Present-day locoregional control in patients with t1 or t2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy
    Ranjna Sharma
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 17:2899-908. 2010
    ..We sought to determine present-day locoregional recurrence (LRR) rates to better understand the role of postmastectomy radiotherapy (PMRT) in women with 0 to 3 positive lymph nodes...
  53. doi request reprint Delays in primary surgical treatment are not associated with significant tumor size progression in breast cancer patients
    Jamie L Wagner
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 254:119-24. 2011
    ..We evaluated the effect of time to surgery on tumor growth by comparing initial imaging and pathologic tumor size estimates. We also determined predictors of delay to surgery...
  54. pmc Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer
    Jennifer K Litton
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Unit 1354, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Oncologist 18:369-76. 2013
    ..The purpose of this analysis was to compare disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) between pregnant and nonpregnant patients with breast cancer...
  55. ncbi request reprint Combined use of clinical and pathologic staging variables to define outcomes for breast cancer patients treated with neoadjuvant therapy
    Jacqueline S Jeruss
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    J Clin Oncol 26:246-52. 2008
    ..We hypothesized that by using clinical and pathologic staging parameters, in conjunction with biologic tumor markers, a novel means of determining prognosis for patients treated with neoadjuvant chemotherapy could be facilitated...
  56. pmc Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome
    Daniel E Abbott
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
    Surgery 151:710-6. 2012
    ..The oncologic benefit of resecting liver metastases in patients with breast cancer is unclear. This study was performed to identify predictors of survival after hepatectomy...
  57. ncbi request reprint Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial
    Kelly K Hunt
    Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Surg 256:428-36. 2012
    ..To determine factors important in local-regional recurrence (LRR) in patients with negative sentinel lymph nodes (SLNs) by hematoxylin and eosin (H&E) staining...
  58. pmc Biologic features and prognosis of ductal carcinoma in situ are not adversely impacted by initial large body mass
    Henry M Kuerer
    Department of Surgical Oncology, DCIS Discovery Enterprise, Unit 1484, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX 77230 1402, USA
    Breast Cancer Res Treat 133:1131-41. 2012
    ..Furthermore, there was no significant difference in risk of recurrence between diabetic patients receiving metformin or not. In conclusion, higher BMI is not associated with adverse biologic features or prognosis in patients with DCIS...
  59. pmc Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes
    Elizabeth A Mittendorf
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:7381-8. 2009
    ..To evaluate HER2 status in residual tumor identified at the time of surgery in patients not achieving a pathologic complete response (pCR) and to determine the effect of alterations in HER2 status on recurrence-free survival (RFS)...
  60. ncbi request reprint Folate receptor α: a storied past and promising future in immunotherapy
    Guy T Clifton
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, Ft Sam Houston, TX, USA
    Hum Vaccin 7:183-90. 2011
    ..This review will cover immunotherapeutic methods, both active and passive, that target FRα...
  61. doi request reprint Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    George E Peoples
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, Fort Sam Houston, San Antonio, Texas 78234, USA
    Clin Cancer Res 14:797-803. 2008
    ..We have conducted two overlapping E75 vaccine trials to prevent recurrence in node-positive (NP) and node-negative (NN) breast cancer patients...
  62. ncbi request reprint Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer
    Elizabeth A Mittendorf
    Clinical Breast Care Project, Department of Surgery, Walter Reed Army Medical Center, 6900 Georgia Avenue NW, Washington, DC 20307 5001, USA
    Surgery 139:407-18. 2006
    ..The purpose of this study was to demonstrate clonal expansion of E75-specific CD8(+) T cells and to identify intra- and interantigenic epitope spreading...
  63. ncbi request reprint Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer: a pilot study
    Alexander Stojadinovic
    Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Ann Surg Oncol 14:3359-68. 2007
    ..Recent advances in the ability to quantify and phenotype circulating tumor cells (CTCs) in breast cancer patients may lead to a role for CTCs in monitoring response to vaccine-based immunotherapy...
  64. ncbi request reprint Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial
    Elizabeth A Mittendorf
    Clinical Breast Care Project, Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Cancer 106:2309-17. 2006
    ..Importantly, a naturally occurring polymorphism (I-->V at position 2, 2VGP2) associated with increased breast cancer risk was addressed...
  65. pmc Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast
    Henry M Kuerer
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:39-47. 2011
    ..Through this study, the authors sought to investigate the biologic and immunologic effects of preoperative trastuzumab in patients with ductal carcinoma in situ (DCIS) of the breast...
  66. doi request reprint Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy
    Min Yi
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Cancer Prev Res (Phila) 3:1026-34. 2010
    ..Evidence-driven models are needed to better inform women of their absolute risk of contralateral breast cancer as well as their competing risk of recurrence from the primary breast cancer to empower them in their active decision making...
  67. doi request reprint Surgical considerations in patients receiving neoadjuvant systemic therapy
    Akhil Chawla
    Department of Surgery, Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH, USA
    Future Oncol 8:239-50. 2012
    ..An ongoing cooperative group trial is investigating the utility of sentinel lymph node surgery in the clinically node-positive population...
  68. doi request reprint The E75 HER2/neu peptide vaccine
    Elizabeth A Mittendorf
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer Immunol Immunother 57:1511-21. 2008
    ..Finally, we present some of the future directions for our Cancer Vaccine Development Program assessing multi-epitope peptide vaccines and combination immunotherapies...
  69. doi request reprint Clinicopathologic factors associated with involved margins after breast-conserving surgery for invasive lobular carcinoma
    Eric J Silberfein
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 10:52-8. 2010
    ..Our goal was to determine whether any specific patient- or disease-related factors influenced margin status...
  70. doi request reprint Gamma probe identification of normal parathyroid glands during central neck surgery can facilitate parathyroid preservation
    Elizabeth G Grubbs
    Section of Endocrine Tumor Surgery, Department of Surgical Oncology, Unit 444, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Boulevard, Box 301402, Houston, TX 77030 4009, USA
    Am J Surg 196:931-5; discussion 935-6. 2008
    ..We evaluated gamma probe identification (GPI) of sestamibi-labeled normal parathyroid glands during central neck surgery...
  71. ncbi request reprint Electrical impedance scanning as a new breast cancer risk stratification tool for young women
    Alexander Stojadinovic
    Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    J Surg Oncol 97:112-20. 2008
    ..The T-Scan(tm2000 (ED is designed to use EIS to identify women ages 30-39 with elevated risk of breast cancer (i.e., T-Scan+ women)...
  72. ncbi request reprint Improvement of sleep disturbance and neurocognitive function after parathyroidectomy in patients with primary hyperparathyroidism
    Elizabeth A Mittendorf
    Department of Surgical Oncology, University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Endocr Pract 13:338-44. 2007
    ..To investigate the frequency of the nontraditional symptoms of sleep disturbance and impaired cognitive functioning in patients with primary hyper-parathyroidism (PHPT) and to assess changes in such patients after parathyroidectomy...
  73. ncbi request reprint Breast cancer vaccines: promise for the future or pipe dream?
    Elizabeth A Mittendorf
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 110:1677-86. 2007
    ..A second strategy for a preventive breast cancer vaccine is to target tumor-associated antigens. Ongoing clinical trials are utilizing this approach, with preliminary results that are encouraging...
  74. doi request reprint Breast cancer vaccines: ongoing National Cancer Institute-registered clinical trials
    Elizabeth A Mittendorf
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Expert Rev Vaccines 10:755-74. 2011
    ..This article focuses on breast cancer vaccines emphasizing delivery platforms, target antigens and novel strategies designed to enhance response to vaccination that are being evaluated in ongoing Phase II clinical trials...
  75. doi request reprint Cancer vaccines: should we be targeting patients with less aggressive disease?
    Diane F Hale
    Department of Surgery, General Surgery Service, Brooke Army Medical Center, San Antonio, TX, USA
    Expert Rev Vaccines 11:721-31. 2012
    ..Data from these trials suggest that cancer vaccines may be more effective in patients with lower volume disease, and data from the E75 peptide vaccine trials suggest that vaccines may be most effective in less aggressive disease...
  76. ncbi request reprint Satisfaction with breast cancer screening and future screening participation
    Alexander Stojadinovic
    Department of Surgery, Walter Reed Army Medical Center, Washington, DC, USA
    Med Sci Monit 13:CR422-9. 2007
    ....
  77. ncbi request reprint Followup of patients with papillary thyroid cancer: in search of the optimal algorithm
    Elizabeth A Mittendorf
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 205:239-47. 2007
    ..Cervical recurrence occurs in up to 30% of patients after surgical treatment for papillary thyroid cancer. This study sought to determine an appropriate algorithm for followup evaluation...
  78. ncbi request reprint Pheochromocytoma: advances in genetics, diagnosis, localization, and treatment
    Elizabeth A Mittendorf
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Unit 444, Houston, TX 77030, USA
    Hematol Oncol Clin North Am 21:509-25; ix. 2007
    ..Surgery remains the definitive treatment, and advances in laparoscopic techniques as well as cortical-sparing procedures have reduced the morbidity associated with tumor resection...
  79. ncbi request reprint Evaluation of the CD107 cytotoxicity assay for the detection of cytolytic CD8+ cells recognizing HER2/neu vaccine peptides
    Elizabeth A Mittendorf
    Clinical Breast Care Project, Department of Surgery, Walter Reed Army Medical Center, Washington, DC 20307 5001, USA
    Breast Cancer Res Treat 92:85-93. 2005
    ..57%, respectively. These results correlated favorably with cytotoxicity as measured by the traditional (51)Cr assay. These findings confirm preliminary reports of the CD107 assay and suggest its usefulness for monitoring cancer trials...
  80. pmc The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1
    Gheath Alatrash
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Immunother 35:309-20. 2012
    ..Our data demonstrate distinct mechanisms for cross-presentation of soluble and cell-associated NE and P3, which may be valuable in understanding immunity to PR1 in leukemia...
  81. ncbi request reprint Core biopsy diagnosis of ductal carcinoma in situ: an indication for sentinel lymph node biopsy
    Elizabeth A Mittendorf
    Comprehensive Breast Center, Clinical Breast Care Project CBCP, Walter Reed Army Medical Center, Washington, DC 20307, USA
    Curr Surg 62:253-7. 2005
    ..The technique has also been applied successfully in patients with ductal carcinoma in situ (DCIS). The purpose of this study was to review our experience performing SLNB in patients with a biopsy diagnosis of DCIS...
  82. doi request reprint Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
    Jarrod P Holmes
    Department of Medicine, Division of Hematology and Medical Oncology, Naval Medical Center San Diego, San Diego, California, USA
    Cancer 113:1666-75. 2008
    ..The optimal biologic dose (OBD) was determined based on toxicity and immunologic response...